Table 1. Baseline characteristics of the study patients infected with SARS-CoV-2.
| Variables | Total (n = 167) | Thrombocytopenia (n = 41) | Non-thrombocytopenia (n = 126) | P value |
|---|---|---|---|---|
| Age, years | 66.00 [58.00–77.00] | 68.00 [61.50–78.50] | 66.00 [57.00–77.00] | 0.16 |
| Gender | 0.34 | |||
| Male | 112 (67.07%) | 25 (60.98%) | 87 (69.05%) | |
| Female | 55 (32.93%) | 16 (39.02%) | 39 (30.95%) | |
| Comorbidities | ||||
| Hypertension | 85 (50.90%) | 22 (53.66%) | 63 (50.00%) | 0.68 |
| Diabetes | 48 (28.74%) | 10 (24.39%) | 38 (30.16%) | 0.48 |
| Coronary heart disease | 39 (23.35%) | 7 (17.07%) | 32 (25.40%) | 0.27 |
| Chronic lung disease | 12 (7.19%) | 3 (7.32%) | 9 (7.14%) | 0.97 |
| Cerebrovascular disease | 36 (21.56%) | 7 (17.07%) | 29 (23.02%) | 0.42 |
| Chronic renal failure | 19 (11.38%) | 4 (9.76%) | 15 (11.90%) | 1.00 |
| Malignant tumor | 9 (5.39%) | 3 (7.32%) | 6 (4.76%) | 0.69 |
| Vital signs | ||||
| Heart rate, beats per minute | 92.25 (19.66) | 93.15 (21.21) | 91.95 (19.21) | 0.74 |
| Respiratory rate, breaths per minute | 23.61 (9.79) | 23.41 (7.13). | 23.67 (10.54) | 0.86 |
| Mean arterial pressure, mmHg | 91.35 (14.82) | 93.78 (14.81) | 90.56 (14.80) | 0.23 |
| Laboratory findings | ||||
| WBC, ×109/L | 8.13 [6.14–11.85] | 7.17 [4.68–9.89] | 8.75 [6.44–12.26] | <0.01 |
| Neutrophilic granulocyte percentage, % | 84.17 [75.05–91.18] | 87.50 [71.70–91.60] | 83.40 [75.10–90.95] | 0.61 |
| Lymphocyte percentage, % | 8.25 [4.10–14.53] | 7.20 [4.00–14.60] | 8.50 [4.25–14.55] | 0.77 |
| Platelet count, ×109/L | 190.00 [126.00–236.00] | 108.00 [77.00–119.50] | 211.50 [176.00–269.50] | <0.01 |
| Creatinine, μmol/L | 68.45 [55.38–107.85] | 78.80 [62.30–126.45] | 65.40 [53.55–97.35] | 0.06 |
| Blood urea, mmol/L | 10.05 [6.28–15.78] | 11.50 [8.80–16.07] | 9.00 [5.75–15.70] | 0.04 |
| AST, IU/L | 36.00 [22.00–63.00] | 50.00 [26.00–80.00] | 36.00 [21.25–61.50] | 0.13 |
| ALT, IU/L | 31.00 [19.60–47.50] | 34.00 [20.00–43.50] | 29.00 [19.40–48.75] | 0.46 |
| Total bilirubin, μmol/L | 10.50 [7.45–15.12] | 13.30 [8.05–22.80] | 10.20 [7.43–13.95] | 0.02 |
| Procalcitonin, ng/mL | 0.17 [0.07–0.57] | 0.29 [0.10–0.72] | 0.15 [0.07–0.47] | 0.06 |
| PT, seconds | 12.95 [11.90–14.45] | 13.20 [11.80–14.85] | 12.90 [11.95–14.20] | 0.96 |
| APTT, seconds | 31.60 [27.88–36.60] | 31.10 [26.75–39.75] | 31.60 [27.95–36.35] | 0.92 |
| hs-CTn I, ng/mL | 0.02 [0.01–0.06] | 0.04 [0.01–0.12] | 0.02 [0.01–0.04] | 0.09 |
| D-dimer, μg/L | 1.99 [0.90–6.61] | 2.26 [0.44–21.22] | 1.97 [0.90–4.42] | 0.22 |
| LDH, U/L | 354.00 [251.00–554.00] | 504.00 [303.50–623.00] | 328.00 [248.00–508.25] | <0.01 |
| APACHE II | 12.00 [9.00–16.00] | 12.00 [10.50–15.50] | 12.00 [9.00–16.00] | 0.72 |
| SOFA | 4.00 [3.00–7.00] | 5.00 [4.00–7.50] | 4.00 [2.00–5.00] | <0.01 |
| Six-point ordinal scale on day 1 | 4.00 [3.00–5.00] | 4.00 [3.00–5.00] | 4.00 [3.00–5.00] | 0.31 |
| 2-hospital admission, not requiring supplemental oxygen | 2(1.20%) | 2(4.88%) | 0.00 | |
| 3-hospital admission, requiring supplemental oxygen | 60 (35.93%) | 9 (21.95%) | 51 (40.48%) | |
| 4-hospital admission, requiring high-flow oxygen therapy or non-invasive ventilation | 60 (35.93%) | 18 (43.90%) | 42 (33.33%) | |
| 5-hospital admission, requiring invasive ventilation or ECMO | 45 (26.95%) | 12 (29.27%) | 33 (26.19%) | |
(WBC) White blood cell; (AST) Aspartate aminotransferase; (ALT) Alanine aminotransferase; (PT) Prothrombin time; (APTT) Activated partial thromboplastin time; (hs-CTn I) Hypersensitive cardiac troponin I; (LDH) Lactate dehydrogenase; (APACHE II) Acute Physiology and Chronic Health Status Score II; (SOFA) Sequential Organ Failure Assessment.